S&P 500 7559.45 +0.21%
NASDAQ 26226.06 +0.07%
TASI 10808.43 -0.42%
Oil (WTI) 71.59 -0.68%
Oil (Brent) 76.06 -0.31%
VIX 15.59 -1.58%
Gold 4112.90 -0.67%
USD/SAR 3.75 +0.01%

Beam Therapeutics Inc.

BEAM · Healthcare · · USD
32.87 USD
0.00 (-8.24%)
● Updated 2026-07-10 17:11 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Mid-term (Position)

73
/ 100
Technical 75
Trend & RS 96
Momentum 67
Fundamental 33
Macro 71
Liquidity 25
ComponentScoreWeight
Technical 75.0 20%
Trend & RS 96.4 30%
Momentum 67.0 15%
Fundamental 33.3 10%
Macro 71.2 20%
Liquidity 25.3 5%

Trade Setup

Entry 33.68
Stop Loss 28.42 (15.6%)
Target 1 (1:1) 38.94 (+15.6%)
Target 2 (2:1) 44.20 (+31.2%)
ATR(14) 2.63 (7.8%)
Risk per Share 5.26
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 75.7 +1.03
Momentum 67.0 +0.68
Quality 36.2 -0.55
Composite 59.6

Quality Scores

Piotroski F-Score 3 /9 — Weak
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio N/A 22.0 Inline
P/B Ratio 2.8 4.0 Below

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Position Sizing — Kelly Criterion

4.8%
Recommended Size
47.4%
Full Kelly
23.7%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 73/100. Estimated win rate 62%, avg win 9.4%, avg loss 3.5%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
50.83
RSI(14)
1.3045
MACD

Relative Strength (RS) IMPROVING

90
/ 99
RS Rating
O'Neil PASS (≥80)
RS vs SPY ↑ RISING (+16.9% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (3d since high)
Sector Outperformance +24.7% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 50.83 NEUTRAL
Macd 1.3045 BEARISH
Ma Cross 31.59 / 27.93 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.15x LOW

Key Levels

LevelPrice
52-Week High38.26
Bollinger Upper38.35
SMA(200)27.93
SMA(50)31.59
SMA(20)33.79
Current Price32.87
Bollinger Lower29.22
52-Week Low15.60
ATR(14)2.63

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

Insufficient data for Wyckoff analysis.

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-07-06 Normal 0.93x Normal bar — no special VSA pattern
2026-07-07 Normal 1.52x Normal bar — no special VSA pattern
2026-07-08 Normal 1.52x Normal bar — no special VSA pattern
2026-07-09 Normal 0.97x Normal bar — no special VSA pattern
2026-07-10 Normal 0.15x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 35.45 Above Kijun
Kijun-sen (26) 33.28 Base line
Senkou A 34.37 Leading span A
Senkou B 32.06 Leading span B
Cloud 32.06 – 34.37 Bullish (Green)
Price vs Cloud 33.68 Inside Cloud
Chikou Span 29.55 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 29.22 – 38.35  |  KC: 29.87 – 37.7

Divergences (last 60 bars)

No significant divergences detected in the last 60 bars.

Anchored VWAP

VWAP: 27.15 Anchor: 2025-08-21 (52w Low) ABOVE AVWAP +24.1%

Heikin-Ashi Trend

EXHAUSTION Trend exhaustion (3 doji candles) Full data via /api/advanced/BEAM

Valuation

MetricValue
Market Cap3.38B
P/E (TTM)N/A
Forward P/EN/A
P/B2.81
EPS-0.49

Financial Health

MetricValue
Revenue Growth3.2%
Profit Margin-40.2%
ROE-5.8%
Debt/Equity21.54
Current Ratio16.99
Dividend YieldN/A
Payout RatioN/A
Beta2.18

Trading Data

32.87
Open
32.87
Day High
32.87
Day Low
276.5K
Volume (0.1x avg)

Recent News (8)

Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?
Simply Wall St. · 2026-07-09
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Zacks · 2026-07-09
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
Investor's Business Daily · 2026-07-08
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
Stocktwits · 2026-07-08
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Motley Fool · 2026-07-08
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
BioPharma Dive · 2026-07-08
Tesla’s 10% Weight in ARKK Sets Up a Make-or-Break Year for the Innovation ETF
24/7 Wall St. · 2026-06-29
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
Zacks · 2026-06-19

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —